John Frew

Prof. John Frew


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Experimental Dermatology
Verified
Journal Article
Open access
PDF file
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
FBFarida Benhadou
Farida Benhadou
ABAngel S. Byrd
Angel S. Byrd
NCNisha S. Chandran
Nisha S. Chandran
EGEvangelos J Giamarellos-Bourboulis
Evangelos J Giamarellos-Bourboulis
HZHessel H. van der Zee
Hessel H. van der Zee
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International Hidradenitis Suppurativa Research Symposium held March 30–April 2, 2006 in Dessau, Germany with 33 participants were prophetic when they wrote “Hopefully, this heralds a welcome new tradition: to get to the molecular heart of HS pathogenesis, which can only be achieved by a renaissance of solid basic HS research, as the key to developing more effective HS therapy.” (Kurzen et al. What causes hidradenitis suppurativa?. Exp Dermatol 2008;17:455). Fifteen years later, there is no doubt that the wished renaissance of solid basic HS research is ongoing with rapid steps and that HS has developed deep roots among inflammatory diseases in Dermatology and beyond, recognized as “the only inflammatory skin disease than can be healed”. This anniversary article of 43 research‐performing authors from all around the globe in the official journal of the European Hidradenitis Suppurativa Foundation e.V. (EHSF e.V.) and the Hidradenitis Suppurativa Foundation, Inc. (HSF USA) summarizes the evidence of the intense HS clinical and experimental research during the last 15 years in all aspects of the disease and provides information of the developments to come in the near future.

1 December 2009 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JFJohn Frew
John Frew
LML.K. Martin
L.K. Martin
TNT. Nijsten
T. Nijsten
Dedee MurrellDedee Murrell
Dedee Murrell

1 December 2013 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
SVSupriya S. Venugopal
Supriya S. Venugopal
WYWenfei Yan
Wenfei Yan
JFJohn Frew
John Frew
HCHeather I. Cohn
Heather I. Cohn
LRLesley M. Rhodes
Lesley M. Rhodes
DMDedee F. Murrell
Dedee F. Murrell

13 December 2018 in F1000Research
Verified
Journal Article
Open access
PDF file
JFJohn Frew
John Frew
JHJason E. Hawkes
Jason E. Hawkes
JKJames G. Krueger
James G. Krueger
Background: The pathogenesis of hidradenitis suppurativa (HS) remains unclear. In order to develop effective treatment strategies, a deeper understanding of pathophysiology is needed. This is impaired by multiple small studies with inconsistent methodologies and the impact of co-occurring pro-inflammatory conditions such as smoking and obesity. Methods: This systematic review aimed to collate all published reports of cytokine studies in tissue, blood, serum and exudate. It was registered with PROSPERO (Registration number CRD42018104664) performed in line with the PRISMA checklist. Results: 19 studies were identified comprising 564 individual HS patients and 198 control patients examining 81 discrete cytokines. Methodology was highly varied and the quality of studies was generally low. There was a large degree of variance between the measured levels of cytokines. 78.2% of cytokines demonstrated heterogeneity by the chi-squared test for homogeneity and hence meta-analysis was not deemed appropriate. However, a strong and significant IL-17 signalling component was identified. Conclusions: Cytokines consistently elevated in lesional, peri-lesional and unaffected tissue are identified and discussed. Areas for further investigation include the role of dendritic cells in HS; the contribution of obesity, smoking, diabetes and the microbiome to cytokine profiles in HS; and examining the natural history of this disease through longitudinal measurements of cytokines over time.

1 July 2020 in JAAD International
Verified
Journal Article
Open access
JFJohn Frew
John Frew
The pathogenic model of hidradenitis suppurativa is in the midst of a paradigm shift away from a disorder of primary follicular occlusion to an autoinflammatory keratinization disease. Observational, experimental, and therapeutic evidence supports the concept of hidradenitis suppurativa as a primarily inflammatory disorder, a disorder of autoimmunity, or both, in contrast to the current prevailing paradigm of primary follicular occlusion. The lack of reliable and high-fidelity disease models has limited the available experimental and mechanistic evidence to support or refute one pathogenic model over another. This scholarly review synthesizes the existing clinical, histologic, and molecular data to evaluate the extant evidence supporting the autoinflammatory paradigm and further informing the molecular mechanisms of hidradenitis suppurativa pathogenesis. Follicular hyperkeratosis/occlusion and perifollicular inflammation coexist in histologic specimens, with interleukin 1α demonstrated to stimulate comedogenesis in the infundibulum. pH elevation in occluded body sites alters the microbiome and amplifies existing T-helper cell type 17 immunoresponses. Known metabolic comorbidities and smoking are known to upregulate interleukin 1α in follicular keratinocytes. Identified genetic variants may alter epidermal growth factor receptor signaling, leading to upregulated keratinocyte inflammatory responses. The process of follicular rupture and dermal tunnel formation can be explained as secondary responses to inflammatory activation of fibroblasts and epithelial-mesenchymal transition, with antibody production associated with inflammatory amplification in advanced disease. This review aims to reevaluate and integrate the current clinical, histologic, and molecular data into a pathogenic model of hidradenitis suppurativa. This is essential to advance our understanding of the disease and identify novel therapeutic targets and approaches.

1 October 2013 in JAMA Dermatology
Verified
Journal Article
Closed access
PDF file
DSDeshan F. Sebaratnam
Deshan F. Sebaratnam
AHAnna Marie Hanna
Anna Marie Hanna
SCShien-Ning Chee
Shien-Ning Chee
JFJohn Frew
John Frew
SVSupriya S. Venugopal
Supriya S. Venugopal
DMDédée F. Murrell
Dédée F. Murrell
Research from JAMA Dermatology — Development of a Quality-of-Life Instrument for Autoimmune Bullous Disease — The Autoimmune Bullous Disease Quality of Life Questionnaire